IFNAR2 and viral load: Ameliorating viral disease with dapsone (Lee et al. 2020a; Kanwar et al. 2021, 2022) or the downstream IFN-stimulated cascade with anti-IFNAR2 in the onset stages of disease (Lee 2022a) must attenuate overactive immune-mediated respiratory inflammatory diseases.